期刊
CANCER LETTERS
卷 453, 期 -, 页码 74-83出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2019.03.037
关键词
Hepatocellular carcinoma; Regorafenib; Sorafenib; Molecular imaging; Therapeutic effects
类别
资金
- National Key Research and Development Plan of China [2017YFA0205200]
- National Natural Science Foundation of China [81871514, 81470083, 81227901]
- Strategic Priority Research Program from Chinese Academy of Sciences [XDB02060010]
- International Innovation Team of CAS [20140491524]
- Beijing Municipal Science and Technology Commission [Z161100002616022]
Sorafenib has been used as a clinical targeted therapy for hepatocellular carcinoma (HCC) for more than a decade. In 2017, regorafenib was approved for HCC treatment and has since been reported to prolong the survival of advanced HCC patients after treatment failure with sorafenib. However, there has been no direct systematic comparison of the therapeutic effects of regorafenib and sorafenib against HCC. In this study, we comprehensively compared the therapeutic effects of sorafenib and regorafenib against HCC in vitro and in vivo using multimodality molecular imaging, which can show molecular and cellular differences at early stages. The side effects of sorafenib and regorafenib were also systematically evaluated. The data showed that compared with sorafenib treatment, regorafenib exerted stronger antitumor and antiangiogenic effects and significantly increased the survival rate of HCC mice. Sorafenib but not regorafenib treatment caused body weight loss and liver and kidney dysfunction, while regorafenib but not sorafenib treatment caused hypertension. Our study may provide an experimental basis for the guidance of clinical HCC targeted treatment with regorafenib and sorafenib.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据